Evaluation of Treatment With Viusid in Post-COVID-19 Syndrome

Launched by CATALYSIS SL · May 30, 2024

Keywords

ClinConnect Summary

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2e) is the pathogen responsible for the 2019 coronavirus disease pandemic (COVID-19), which has caused global health care crises and overstretched health care resources, Scientific and clinical evidence is evolving on the subacute and long-term effects of COVID-19, which can affect multiple organ systems. As the population of patients recovering from COVID-19 grows, it is critical to establish an understanding of the healthcare issues surrounding them. COVID-19 is now recognized as a multi-organ disease with a broad spectrum of manif...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Patients with one or more of the following symptoms, persistent after suffering COVID-19:
• • Extreme tiredness (Fatigue).
• • Shortness of breath
• • Chest pain
• • Problems with memory or concentration ("Brain fog")
• • Insomnia
• • Palpitations
• • Dizziness
• • Tingling
• • Joint pain
• • Depression and anxiety
• • Tinnitus or ear pain
• • Malaise, diarrhea, stomach pain, loss of appetite
• • Fever, cough, headache, dry throat, changes in sense of smell or taste
• • Rash
• Exclusion Criteria:
• • Patients with a positive diagnosis of COVID-19 in the last 14 days.
• • Patients who have presented symptoms similar to Post-COVID syndrome prior to the onset of COVID-19 due to a concomitant disease.